The thyroid hormone–inactivating enzyme type 3 deiodinase (D3) is induced during hypertrophic and ischemic cardiomyopathy, leading to a state of local cardiac hypothyroidism. Whether D3 induction occurs in dilated cardiomyopathy is unknown.
Methods:
This study characterized changes in cardiac D3 and thyroid hormone signaling in a transgenic model of progressive dilated cardiomyopathy (TG9 mice).
Results:
Cardiac D3 was dramatically induced 15-fold during the progression of dilated cardiomyopathy in TG9 mice. This D3 induction localized to cardiomyocytes and was associated with a decrease in myocardial thyroid hormone signaling.
Conclusions:
Cardiac D3 is induced in a mouse model of dilated cardiomyopathy, indicating that D3 induction may be a general response to diverse forms of cardiomyopathy.
AscheimDD, HryniewiczK. 2002. Thyroid hormone metabolism in patients with congestive heart failure: the low triiodothyronine state. Thyroid, 12:511–515.
7.
IervasiG, PingitoreA, LandiP, RacitiM, RipoliA, ScarlattiniM, L'AbbateA, DonatoL. 2003. Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 107:708–713.
8.
WangW, GuanH, GerdesAM, IervasiG, YangY, TangYD. 2015. Thyroid status, cardiac function, and mortality in patients with idiopathic dilated cardiomyopathy. J Clin Endocrinol Metab, 100:3210–3218.
9.
UtigerRD. 1995. Altered thyroid function in nonthyroidal illness and surgery. To treat or not to treat? N Engl J Med, 333:1562–1563.
10.
De GrootLJ. 1999. Dangerous dogmas in medicine: the nonthyroidal illness syndrome. J Clin Endocrinol Metab, 84:151–164.
MoruzziP, DoriaE, AgostoniPG, CapacchioneV, SganzerlaP. 1994. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol, 73:374–378.
13.
MoruzziP, DoriaE, AgostoniPG. 1996. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med, 101:461–467.
14.
PingitoreA, GalliE, BarisonA, IervasiA, ScarlattiniM, NucciD, L'AbbateA, MariottiR, IervasiG. 2008. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab, 93:1351–1358.
HuangSA. 2005. Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid, 15:875–881.
19.
WassenFW, SchielAE, KuiperGG, KapteinE, BakkerO, VisserTJ, SimonidesWS. 2002. Induction of thyroid hormone-degrading deiodinase in cardiac hypertrophy and failure. Endocrinology, 143:2812–2815.
20.
PolCJ, MullerA, SimonidesWS. 2010. Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem?. Heart Fail Rev, 15:133–142.
21.
TrivieriMG, OuditGY, SahR, KerfantBG, SunH, GramoliniAO, PanY, WickendenAD, CroteauW, Morreale de EscobarG, PekhletskiR, St GermainD, MaclennanDH, BackxPH. 2006. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc Natl Acad Sci U S A, 103:6043–6048.
22.
UetaCB, OskoueiBN, OlivaresEL, PintoJR, CorreaMM, SimovicG, SimonidesWS, HareJM, BiancoAC. 2012. Absence of myocardial thyroid hormone inactivating deiodinase results in restrictive cardiomyopathy in mice. Mol Endocrinol, 26:809–818.
23.
PolCJ, MullerA, ZuidwijkMJ, van DeelED, KapteinE, SabaA, MarchiniM, ZucchiR, VisserTJ, PaulusWJ, DunckerDJ, SimonidesWS. 2011. Left-ventricular remodeling after myocardial infarction is associated with a cardiomyocyte-specific hypothyroid condition. Endocrinology, 152:669–679.
24.
OlivaresEL, MarassiMP, FortunatoRS, da SilvaAC, Costa-e-SousaRH, AraujoIG, MattosEC, MasudaMO, MulcaheyMA, HuangSA, BiancoAC, CarvalhoDP. 2007. Thyroid function disturbance and type 3 iodothyronine deiodinase induction after myocardial infarction in rats a time course study. Endocrinology, 148:4786–4792.
PolCJ, MullerA, JanssenR, ZuidwijkMJ, dos RemediosCG, VisserTJ, PaulusWJ, SimonidesWS. 2011. Cardiac induction of the thyroid hormone degrading enzyme deiodinase type III in human ischemic cardiomyopathy. Abstract presented at the 93rd Annual Meeting of the Endocrine Society (ENDO 2011), Boston, Massachusetts, June4–7. Abstract no. P1-785.
RichardK, HumeR, KapteinE, SandersJP, van ToorH, De HerderWW, den HollanderJC, KrenningEP, VisserTJ. 1998. Ontogeny of iodothyronine deiodinases in human liver. J Clin Endocrinol Metab, 83:2868–2874.
29.
ZavackiAM, YingH, ChristoffoleteMA, AertsG, SoE, HarneyJW, ChengSY, LarsenPR, BiancoAC. 2005. Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse. Endocrinology, 146:1568–1575.
30.
BiancoAC, AndersonG, ForrestD, GaltonVA, GerebenB, KimBW, KoppPA, LiaoXH, ObregonMJ, PeetersRP, RefetoffS, SharlinDS, SimonidesWS, WeissRE, WilliamsGR, ActionATATFoAaStITHEa. 2014. American Thyroid Association guide to investigating thyroid hormone economy and action in rodent and cell models. Thyroid, 24:88–168.
31.
HuangSA, DorfmanDM, GenestDR, SalvatoreD, LarsenPR. 2003. Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. J Clin Endocrinol Metab, 88:1384–1388.
32.
HuangSA, FishSA, DorfmanDM, SalvatoreD, KozakewichHP, MandelSJ, Larsen PR 2002 A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3. iodothyronine deiodinase. J Clin Endocrinol Metab, 87:4457–4461.
33.
CastronevesLA, JugoRH, MaynardMA, LeeJS, WassnerAJ, DorfmanD, BronsonRT, UkomaduC, AgostonAT, DingL, LuongoC, GuoC, SongH, DemchevV, LeeNY, FeldmanHA, VellaKR, PeakeRW, HartiganC, KelloggMD, DesaiA, SalvatoreD, DenticeM, HuangSA. 2014. Mice with hepatocyte-specific deficiency of type 3 deiodinase have intact liver regeneration and accelerated recovery from nonthyroidal illness after toxin-induced hepatonecrosis. Endocrinology, 155:4061–4068.
34.
PeetersRP, WoutersPJ, KapteinE, van ToorH, VisserTJ, Van den BergheG. 2003. Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. J Clin Endocrinol Metab, 88:3202–3211.
35.
HuangSA, BiancoAC. 2008. Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab, 4:148–155.
36.
FruhwaldFM, Ramschak-SchwarzerS, PichlerB, WatzingerN, SchumacherM, ZweikerR, KleinW, EberB. 1997. Subclinical thyroid disorders in patients with dilated cardiomyopathy. Cardiology, 88:156–159.
37.
KahalyGJ, DillmannWH. 2005. Thyroid hormone action in the heart. Endocr Rev, 26:704–728.
38.
DanziS, KleinI. 2014. Thyroid disease and the cardiovascular system. Endocrinol Metab Clin North Am, 43:517–528.
39.
PachuckiJ, HopkinsJ, PeetersR, TuH, CarvalhoSD, KaulbachH, AbelED, WondisfordFE, IngwallJS, LarsenPR. 2001. Type 2 iodothyronin deiodinase transgene expression in the mouse heart causes cardiac-specific thyrotoxicosis. Endocrinology, 142:13–20.
HongEG, KimBW, JungDY, KimJH, YuT, Seixas Da SilvaW, FriedlineRH, BiancoSD, SeslarSP, WakimotoH, BerulCI, RussellKS, LeeKW, LarsenPR, BiancoAC, KimJK. 2013. Cardiac expression of human type 2 iodothyronine deiodinase increases glucose metabolism and protects against doxorubicin-induced cardiac dysfunction in male mice. Endocrinology, 154:3937–3946.
42.
KesslerEL, BoulaksilM, van RijenHV, VosMA, van VeenTA. 2014. Passive ventricular remodeling in cardiac disease: focus on heterogeneity. Front Physiol, 5:482.
43.
McNallyEM, BarefieldDY, PuckelwartzMJ. 2015. The genetic landscape of cardiomyopathy and its role in heart failure. Cell Metab, 21:174–182.
44.
KrishnanJ, SuterM, WindakR, KrebsT, FelleyA, MontessuitC, Tokarska-SchlattnerM, AasumE, BogdanovaA, PerriardE, PerriardJC, LarsenT, PedrazziniT, KrekW. 2009. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab, 9:512–524.
45.
ZolkO, SolbachTF, EschenhagenT, WeidemannA, FrommMF. 2008. Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure. Biochem Biophys Res Commun, 376:315–320.
46.
DenticeM, AmbrosioR, DamianoV, SibilioA, LuongoC, GuardiolaO, YennekS, ZordanP, MinchiottiG, ColaoA, MarsiliA, BrunelliS, Del VecchioL, LarsenPR, TajbakhshS, SalvatoreD. 2014. Intracellular inactivation of thyroid hormone is a survival mechanism for muscle stem cell proliferation and lineage progression. Cell Metab, 20:1038–1048.
